tildacerfont
Generic: Tildacerfont
tildacerfont: developed by 1 company · 1 clinical trial tracked. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| SPRUCE BIOSCIENCES, INC. (SPRB) | Phase 2 |
Clinical Trials (1)
A Phase 2 Study to Evaluate the Safety, Efficacy and Pharmacokinetics of SPR001 (Tildacerfont) in Children Aged 2 to 17 Years With Congenital Adrenal Hyperplasia (CAH)
Frequently asked questions
Who is developing tildacerfont?
tildacerfont is being developed by SPRUCE BIOSCIENCES, INC..
How many clinical trials involve tildacerfont?
BioSniper tracks 1 clinical trial involving tildacerfont.
Get deeper analysis on tildacerfont
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis